

PROVIDING INNOVATIVE PRODUCTS TO PARTNERS, PATIENTS AND CAREGIVERS




COMPANY HIGHLIGHTS

- Founded in 1999
- Privately held by Gurnet Point Capital and Webster Equity Partners
- FDA/DEA registered facilities
- Transdermal/oral thin film experts
- Rx and OTC manufacturing
- 50+ issued patents

ADVANTAGES OF TRANSDERMAL DELIVERY

- Bypasses first pass metabolism
- Sustained delivery for multiple days of therapy
- Possibility of improved patient compliance
- Easier drug administration — no food effect, eliminates dosing/timing issues
- Potential for fewer side effects
- Design is more abuse resistant than other dosage forms
- Avoids swallowing issues prevalent with certain diseases



Corium Innovations: Experienced Team Solves Complex Delivery Issues

Corium Innovations is a premier contract development and manufacturing organization (CDMO) that has a nearly 25-year history of successfully developing and manufacturing transdermal patches and oral thin film dosage forms to solve complex delivery problems that impact both patients and partners. The company maintains significant expertise in developing these unique product offerings that provide specific advantages to the patient experience and stands ready to assist partners in a broad array of film-based product needs from our FDA-registered, U.S. location in Grand Rapids, Michigan. With nearly 200,000 square feet of GMP facilities, we currently have annual capacity to produce over 200 million patches/films, including primary and secondary packaging options for a turnkey, readily saleable product cycle.

Corium Innovations has patents covering its transdermal delivery platforms that can be deployed to support your specific product needs.


Platform Technologies That Provide Innovative Delivery Solutions

Corplex™ is our flagship matrix patch technology, which is the subject of several US and international patents. These fundamentally cover a broad range of **adhesive systems** and **bioavailability enhancement** approaches for small molecules. The recently FDA-approved product Adlarity®, a 7-day continuous delivery patch containing the widely prescribed drug donepezil for the treatment of Alzheimer's Disease, was developed via the Corplex platform¹. The innovation driver for this product is the **in-patch** conversion process to transform the salt form of drug to a higher bioavailability, free-base form of donepezil that results in higher levels of drug being absorbed across the skin. In addition, the transdermal delivery of donepezil potentially results in fewer GI-related adverse events relative to oral delivery of the drug.

Here are some key features of Corplex technology:

- ✓ Range of adhesive properties for aqueous and lipid delivery
- ✓ Improved drug bioavailability and high drug loading
- ✓ Excellent adhesion to both wet and dry surfaces
- ✓ Flexibility with natural skin movement
- ✓ Continuous delivery to 7 days from a single patch
- ✓ Patent protection

CORPLEX™ 6-LAYER PATCH





PARTNERSHIP TYPES

- Products (feasibility and/or clinical studies completed) available for license
- Co-development programs
- Manufacturing supply
- Life Cycle Management

PARTNERING WITH US FOR SUCCESS

Corium Innovations currently manufactures both prescription and consumer products for several partners across a multitude of therapeutic areas. Our customer service and on-time delivery are hallmark to Corium Innovations. Consider our team to support your next transdermal patch or oral thin film product. We can provide assistance in the following areas depending upon your marketing needs:

- Innovative, patented products for specialty pharmaceutical companies
- Life Cycle Management expertise for new chemical entities
- Bioequivalent products for the lower-cost, generic market
- Unique OTC consumer products that provide market differentiation

Please reach out to our business development team for further information:



Kevin Ostrander MS, MBA
 Chief Business Officer
 ✉ kevin.ostrander@coriumintl.com or
 ✉ BizDev@coriumintl.com
 ☎ (908) 240-4486



Dwayne Sharpe
 Director of Business Development
 ✉ dwayne.sharpe@coriumintl.com
 ☎ (636) 734-5123
 🌐 coriuminv.com

Oral Thin Film Strips

Leveraging our existing manufacturing capabilities and equipment, Corium can manage the development and production of your next oral thin film (OTF) product. OTFs are thin, small (less than a postage stamp) biodegradable film strips containing drug substance that are designed primarily to be placed either sublingually or on the buccal mucosa (inside cheek). They are comprised of polymers that readily dissolve over a specified time period when placed in contact with saliva generated in the oral cavity. Corium has significant experience developing generic products in this dosage form.

Key attributes for consideration include:

- ✓ Small, convenient dosage form
- ✓ Rapid systemic absorption
- ✓ Avoids first-pass metabolism
- ✓ Possibility for lowering adverse events
- ✓ Daily drug dosing



Manufacturing Excellence

Corium Innovations offers a full array of services and manufacturing capabilities from modern facilities in the United States. We are FDA-registered, DEA licensed (II-V) and ISO 9001 and ISO 13485 certified. Our team members have extensive knowledge of the chemistry, manufacturing and controls (CMC) for transdermal and oral thin film products and can assist in the following areas:

Development and Scale-up

- ✓ Formulation and process engineering
- ✓ Analytical method development and validation
- ✓ Phase I/II protocol design and implementation

Manufacturing and Testing

- ✓ Compounding and extrusion processing
- ✓ Coating, drying and laminating processes
- ✓ Die cutting and customization
- ✓ Physical and chemical testing
- ✓ Primary, secondary and tertiary packaging